NCT03597022 - Multiple Escalating Dose Study of BAY1093884 in Adults With Hemophilia A or B With or Without Inhibitors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 24, 2018

Primary Completion Date

October 15, 2019

Study Completion Date

October 15, 2019

Conditions

Hemophilia A and B

Interventions

DRUG

Befovacimab (BAY1093884)

Once weekly doses until premature termination of the study, subcutaneous injection

Trial Locations (17)

1090

Universitätsklinikum AKH Wien, Vienna

1756

SHATHD Spec. Hospi. for Active Treatm. of Haematol. Dis. EAD, Sofia

4000

Medical centre Hipokrat - N EOOD, Plovdiv

6150

Fiona Stanley Hospital, Murdoch

7624

Pecsi Tudomanyegyetem Klinikai Kozpont, Pécs

8011

Haematology Service, Canterbury Health Laboratories, Christchurch

9010

MHAT Sveta Marina EAD, Varna

20122

Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan

35233

Eulji University Hospital, Daejeon

50006

Changhua Christian Hospital, Changhua

51092

Hôpital Robert Debré - Reims Cedex, Reims

69500

Hôpital Louis Pradel - Bron, Bron

167-0035

Ogikubo Hospital, Suginami

734-8551

Hiroshima University Hospital, Hiroshima

CF14 4XW

University Hospital of Wales, Cardiff

NW3 2QG

Royal Free Hospital, London

M13 9WL

Manchester Royal Infirmary, Manchester